#### Please fax both pages of completed form to your team at 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to <u>MyAccredoPatients.com</u> to log in or get started.

#### Prescription & Enrollment Form Pediatric Growth Disorders



Four simple steps to submit your referral.

# **1** Patient Information

Please provide copies of front and back of all medical and prescription insurance cards.

New patient Current patie	ent		
Patient's first name		Last name	Middle initial
Preferred patient first name		Preferred patie	ent last name
Sex at birth: Male Female	Gender identity	Pronouns	Last 4 digits of SSN
Date of birth	Street address		Apt #
City		State	Zip
Home phone	Cell phone	Emai	il address
Parent/guardian (if applicable)			
			il address
Alternate caregiver/contact			
Home phone	Cell phone	Emai	il address
OK to leave message with alte	rnate caregiver/contact		
Patient's primary language: E	nglish Other If other, ple	ase specify	

### **2** Prescriber Information

All fields must be completed to expedite prescription fulfillment.

Date	Time	Da	ate medication needed		
Office/clinic/institution name					
Prescriber's first name			Last name		
Prescriber's title		If NP o	r PA, under direction o	f Dr	
Office phone	Fax		. NPI #	License #	
Office contact and title			Office contact em	ail	
Office street address				Suite #	
City		State		Zip	
Deliver product to: Prescriber's of	fice Patient's home				

# **3** Clinical Information

Primary ICD-10 code (REQUIRED):				Weight (kg)_	Height (cm)	
Date measured	Injection training needed:	Yes	No	By:	MD office	Other
If prior HgH use, date started	NKDA	Kno	own dru	g allergi	ies	
Concurrent meds						

Please attach the following information for growth disorder diagnosis: Drug profile, labs, growth chart where applicable

Patient's first name	Last name	Middle initial	Date of birth
Prescriber's first name	Last name	Phone	

### **4** Prescribing Information

Medication	Strength/Formulation Dir	rections Quantity/Refills
Genotropin <sup>®</sup> (somatropin)	5mg cartridge 12mg cartridge	1-month supply 3-month supply
	Mini Quick <sup>®</sup> prefilled syringe	Other
	0.2mg (1-mo) 0.4mg 0.6mg 0.8mg 1mg 1.2mg (1-mo) 1.4mg 1.6mg 1.8mg 2mg	Refills
Humatrope <sup>®</sup> (somatropin)	5mg vial 6mg cartridge 12mg cartridge 24mg cartridge	
HumatroPen® (somatropin) injection device for cartridge	6mg device 12mg device 24mg device	
Increlex <sup>®</sup> (mecasermin)	40mg/4mL vial	
Ngenla® (somatrogon-ghla)	24mg/1.2mL Prefilled Pen 60mg/1.2mL Prefilled Pen	
Norditropin® (somatropin)	FlexPro <sup>®</sup> prefilled pen 5mg 10mg 15mg 30mg	
Nutropin (somatropin)	AQ NuSpin <sup>®</sup> prefilled device 5mg 10mg 20mg	
Omnitrope <sup>®</sup> (somatropin)	5.8mg vial 5mg/1.5mL cartridge 10mg/1.5mL cartridge	
Sogroya® (somapacitan- beco)	Prefilled pen 5mg 10mg 15mg	
Skytrofa <sup>®</sup> (lonapegsoma- tropin-tcgd)	3mg cartridge3.6mg cartridge4.3mg cartridge5.2mg cartridge6.3mg cartridge7.6mg cartridge9.1mg cartridge11mg cartridge13.3mg cartridge	
Zomacton® (somatropin)	5mg vial 10mg vial	
Other		1-month supply 3-month supply
		Other
		Refills
	rescriber to strike through if not required) oplies such as needles, syringes, sterile water, etc. and home medic	cal equipment necessary to Send quantity sufficient for medication days supply

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

I certify that this medication is not being prescribed for anti-aging, cosmetic or athletic performance. I further certify human growth hormone is being prescribed for the medical condition noted above and is medically necessary.

#### Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN	
HERE	

Dispense as written

Date

Substitution allowed

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



Date

The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2023 Accredo Health Group, Inc. I An Express Scripts Company. All rights reserved. GDT-00002-H-122723 CRP2501\_15473

# **FOR REFERENCE ONLY:** This page is for reference only and should not be returned. Diagnosis must be indicated in section 3 of the enrollment form.

COMMON DIAGNOSIS CODES	
B20 Human immunodeficiency virus [HIV] disease	Congenital disease & associated disorders:
With: <b>R64</b> Cachexia (Serostim <sup>®</sup> only)	Q96.9 Turner's syndrome
With: <b>E88.1</b> Lipodystrophy (Egrifta <sup>®</sup> only)	Q87.1 Noonan syndrome
E23.0 Idiopathic growth hormone deficiency:	Q87.1 Prader-Willi syndrome
Childhood-onset Adult-onset	E34.3, Q78.8 SHOX deficiency
E34.3 Short stature due to endocrine disorder	Q87.1 Russell-Silver syndrome
E23.0 Acquired growth hormone deficiency with:	<b>Q89.8</b> Other specified congenital malformations
Childhood-onset Adult-onset	R62.50 Severe IGF-1 deficiency (Increlex <sup>®</sup> only)
C75.1 Malignant neoplasm of pituitary gland	R62.52 Small for Gestational Age with inadequate
C75.2 Malignant neoplasm of craniopharyngeal duct	catch-up growth (child):
D35.2 Benign neoplasm of pituitary gland	P05.10 Small for gestational age
D35.3 Benign neoplasm of craniopharyngeal duct	P05.00 Light for gestational age
E23.0 Hypopituitarism	P05.9 Slow intrauterine growth
E23.1 Drug-induced hypopituitarism	<b>R62.52</b> Idiopathic Short Stature (child) with – 2.25 SDS
E89.3 Postprocedural hypopituitarism	K91.2 Short-bowel Syndrome (Zorbtive® only)
E23.3 Hypothalamic dysfunction	
N18.9 Chronic kidney disease (child, pre-transplant):	
HD  CAPD  CCPD, schedule:	
N18.2 CKD, Stage II (Mild)	
N18.3 CKD, Stage III (Moderate)	
N18.4 CKD, Stage IV (Severe)	
N18.5 CKD, Stage V	
N18.6 End stage renal disease	